State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai, 201203, China.
Acta Pharmacol Sin. 2022 Dec;43(12):3080-3095. doi: 10.1038/s41401-022-00983-7. Epub 2022 Sep 16.
Traditional medicine has provided a basis for health care and disease treatment to Chinese people for millennia, and herbal medicines are regulated as drug products in China. Chinese herbal medicines have two features. They normally possess very complex chemical composition. This makes the identification of the constituents that are together responsible for the therapeutic action of an herbal medicine challenging, because how to select compounds from an herbal medicine for pharmacodynamic study has been a big hurdle in such identification efforts. To this end, a multi-compound pharmacokinetic approach was established to identify potentially important compounds (bioavailable at the action loci with significant exposure levels after dosing an herbal medicine) and to characterize their pharmacokinetics and disposition. Another feature of Chinese herbal medicines is their typical use as or in combination therapies. Coadministration of complex natural products and conventional synthetic drugs is prevalent worldwide, even though it remains very controversial. Natural product-drug interactions have raised wide concerns about reduced drug efficacy or safety. However, growing evidence shows that incorporating Chinese herbal medicines into synthetic drug-based therapies delivers benefits in the treatment of many multifactorial diseases. To address this issue, a drug-combination pharmacokinetic approach was established to assess drug-drug interaction potential of herbal medicines and degree of pharmacokinetic compatibility for multi-herb combination and herbal medicine-synthetic drug combination therapies. In this review we describe the methodology, techniques, requirements, and applications of multi-compound and drug-combination pharmacokinetic research on Chinese herbal medicines and to discuss further development for these two types of pharmacokinetic research.
传统医学为中国人提供了几千年的医疗保健和疾病治疗基础,草药在我国被视为药品。中草药有两个特点。它们通常具有非常复杂的化学成分。这使得确定共同负责草药治疗作用的成分变得具有挑战性,因为如何从草药中选择化合物进行药效学研究一直是这种鉴定工作中的一个重大障碍。为此,建立了多化合物药代动力学方法来识别潜在的重要化合物(在给予草药后作用部位具有显著暴露水平的可生物利用的化合物),并对其药代动力学和处置进行特征描述。中草药的另一个特点是它们通常作为或联合治疗使用。复杂的天然产物和传统合成药物的联合给药在全球范围内很普遍,尽管这仍然存在很大争议。天然产物-药物相互作用引起了人们对药物疗效降低或安全性降低的广泛关注。然而,越来越多的证据表明,将中草药纳入基于合成药物的治疗方案可以为许多多因素疾病的治疗带来益处。为了解决这个问题,建立了药物联合药代动力学方法来评估草药的药物相互作用潜力以及多草药联合和草药-合成药物联合治疗的药代动力学兼容性程度。在这篇综述中,我们描述了多化合物和药物联合药代动力学研究的方法学、技术、要求和应用,以及对这两种药代动力学研究的进一步发展。